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Abstract 
Background: Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a severely debilitat‑
ing condition of unknown etiology. The symptoms and risk factors of ME/CFS share features of accelerated aging 
implicated in several diseases. Using telomere length as a marker, this study was performed to test the hypothesis that 
ME/CFS is associated with accelerated aging.
Methods: Participant (n = 639) data came from the follow‑up time point of the Georgia CFS surveillance study. 
Using the 1994 CFS Research Case Definition with questionnaire‑based subscale thresholds for fatigue, function, 
and symptoms, participants were classified into four illness groups: CFS if all criteria were met (n = 64), CFS‑X if CFS 
with exclusionary conditions (n = 77), ISF (insufficient symptoms/fatigue) if only some criteria were met regardless 
of exclusionary conditions (n = 302), and NF (non‑fatigued) if no criteria and no exclusionary conditions (n = 196). 
Relative telomere length (T/S ratio) was measured using DNA from whole blood and real‑time PCR. General linear 
models were used to estimate the association of illness groups or T/S ratio with demographics, biological measures 
and covariates with significance set at p < 0.05.
Results: The mean T/S ratio differed significantly by illness group (p = 0.0017); the T/S ratios in CFS (0.90 ± 0.03) 
and ISF (0.94 ± 0.02) were each significantly lower than in NF (1.06 ± 0.04). Differences in T/S ratio by illness groups 
remained significant after adjustment for covariates of age, sex, body mass index, waist–hip ratio, post‑exertional 
malaise and education attainment. Telomere length was shorter by 635, 254 and 424 base pairs in CFS, CFS‑X and ISF, 
respectively, compared to NF. This shorter telomere length translates to roughly 10.1–20.5, 4.0–8.2 and 6.6–13.7 years 
of additional aging in CFS, CFS‑X and ISF compared to NF respectively. Further, stratified analyses based on age 
and sex demonstrated that the association of ME/CFS with short telomeres is largely moderated by female sub‑
jects < 45 years old.
Conclusions: This study found a significant association of ME/CFS with premature telomere attrition that is largely 
moderated by female subjects < 45 years old. Our results indicate that ME/CFS could be included in the list of condi‑
tions associated with accelerated aging. Further work is needed to evaluate the functional significance of accelerated 
aging in ME/CFS.
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Background
Chronic fatigue syndrome (CFS), also known as myal-
gic encephalomyelitis (ME) or systemic exertion intol-
erance disease, is a severely debilitating condition of 
unknown etiology [1]. Clinically, ME/CFS is character-
ized by chronic (longer than 6  months) multi-system 
symptoms including post-exertional malaise (PEM), 
unrefreshing sleep, significant fatigue, pain, muscle 
weakness, and cognitive impairment [1–3]. Proposed 
risk factors for ME/CFS include altered immunity, 
infection, environmental exposures, allergies, genetics, 
as well as physiological and psychological stress act-
ing through alterations in immune and inflammatory 
responses [1]. The symptoms and risk factors for ME/
CFS have features in common with those for acceler-
ated aging/premature immunosenescence. Accelerated 
aging has been implicated in several diseases and poor 
health outcomes [4–10] and telomere length is a widely 
used marker of accelerated aging [11].
Telomeres are several thousand repeats of TTA GGG 
nucleotide sequences that cap the ends of linear chro-
mosomes. Telomeres shorten during every round of 
cell replication because of the end-replication problem, 
and thus telomere length represents the replicative his-
tory of cells and dictates cells’ life span [12]. Because of 
the gradual erosion of telomeres with each cell division, 
age is the strongest predictor of an individual’s telomere 
length. However, several reports indicate sex differences 
where age-adjusted leukocyte telomere length was found 
to be longer in adult women than men [13, 14]. Addition-
ally, telomere length is also impacted by other genetic, 
epigenetic, physiological and environmental factors. 
These factors contribute to variability in both the abso-
lute telomere length and the rate of telomere shorten-
ing among individuals [11]. Chronic inflammation and 
oxidative stress may increase telomere attrition, poten-
tially explaining the association of accelerated telomere 
shortening with disease [6, 7]. We hypothesize that ME/
CFS is associated with accelerated aging and that shorter 
telomeres will serve as a marker of this association. We 
tested our hypothesis based on telomere length deter-
mined using DNA from whole blood with emphasis on 
a number of demographic, metabolic and allostatic load 
variables that are likely to impact the association between 
ME/CFS status and telomere length [2, 4, 7, 8, 11, 15–19]. 
Our results demonstrate significant telomere shortening 
in participants with ME/CFS and other fatigue groups in 
the overall study sample, with stratified analyses reveal-
ing significant premature telomere attrition in fatigued 
female participants  <  45  years old. These findings sup-
port incorporating the model of premature and acceler-
ated immunosenescence in future studies of ME/CFS 
pathophysiology.
Methods
Data sources and study sample
Data came from the follow-up phase of a two-wave pop-
ulation-based longitudinal study of CFS and fatiguing 
illness in Georgia, USA, conducted in 2004 and 2009 [2, 
20]. The study was approved by the Institutional Review 
Boards of the Centers for Disease Control & Prevention, 
Atlanta, GA and Abt Associates, Atlanta, GA. All partici-
pants gave written informed consent for participating in 
the study.
The current analysis focused on data from the clini-
cal evaluation of the follow-up phase, which included a 
detailed medical history, physical exam, laboratory tests, 
and psychiatric evaluation via the Structured Clinical 
Interview for DSM Disorders (SCID). Participants also 
completed a number of questionnaires including a demo-
graphics form, the 20-item Multidimensional Fatigue 
Inventory (MFI-20) [21], the 36-item Short Form Health 
Survey (SF-36 v2) [22, 23], and the CDC Symptom Inven-
tory (SI) [24]. Demographic information was collected 
during a phone interview and further confirmed at the 
in-person clinical evaluation. Vital signs including heart 
rate (bpm), systolic and diastolic blood pressure (mmHg), 
height, weight, and waist and hip circumferences were 
collected at the clinic as part of the physical exam. The 
derived measures, body mass index (BMI) and waist to 
hip ratio (WHR) were calculated [BMI = weight/height2 
(kg/m2)]; [WHR  =  waist/hip (cm/cm)]. The analysis 
included biological measures from Quest Laboratory 
test results such as HDL cholesterol (mg/dL), triglycer-
ides (mg/dL), fasting glucose (mg/dL), insulin (µIU/mL), 
C-reactive protein (CRP, mg/dL), and albumin (g/dL).
Participants were classified as CFS if they met the 1994 
international research definition applied using previously 
described methods [2]. Those with unexplained chronic 
illness with insufficient symptoms/fatigue to meet all of 
the criteria for CFS were grouped as insufficient symp-
toms/fatigue (termed as ISF). Participants meeting none 
of the criteria for CFS were grouped as non-fatigued (NF) 
controls. Additionally, participants in each group were 
broken into those with and without exclusionary medi-
cal/psychiatric conditions [25]. Of the 751 participants 
who were clinically evaluated in the GA CFS surveillance 
study, 71 met all the criteria for CFS without exclusionary 
conditions (CFS group), 78 met all the criteria for CFS 
but with exclusionary conditions (CFS-X group), 340 met 
the criteria for ISF regardless of exclusionary conditions, 
212 met the criteria for NF controls without exclusion-
ary conditions, 47 met the criteria for NF with exclusions 
and 3 participants were classified as “indeterminate” due 
to incomplete information for case definition criteria. We 
excluded participants with indeterminate classification, 
NF with medical/psychiatric exclusion, those missing 
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data on fasting glucose and those with insufficient DNA 
for analysis, leaving 639 participants in 4 illness groups: 
64 CFS, 77 CFS-X, 302 ISF (with and without exclu-
sionary conditions), and 196 NF without exclusionary 
conditions.
Determination of relative telomere length (T/S ratio)
Relative telomere length was measured based on a widely 
used real-time PCR protocol [26] with modifications as 
described below. The assay is based on telomere-specific 
primers’ ability to generate a signal proportional to the 
total summed length of all the telomeres in the cell. This 
telomere signal is normalized to the signal from prim-
ers that amplify the single copy gene, 36B4 that encodes 
the acidic ribosomal phosphoprotein P0 (also known as 
RPLP0). The ratio of telomere (T) signal to the single 
copy gene (S) signal (expressed as T/S ratio) is propor-
tional to the average telomere length per cell. This ratio is 
expressed relative to a reference DNA (K562 DNA from 
Promega Corporation, Madison, WI) which is assigned a 
T/S ratio of 1.0 as it is always compared to itself.
DNA from whole blood collected in PAXgene tubes 
was extracted following the manufacture’s protocol 
(Qiagen, Valencia, CA). DNA quality and quantity were 
assessed by 0.8% agarose gel electrophoresis and Nan-
odrop spectrophotometer (Thermo Scientific, Wilm-
ington, DE) respectively. LightCycler 480 (Roche Life 
Science, Indianapolis, IN) was used for real time PCR 
that consisted of a 20 µL reaction containing 30 ng DNA, 
1X SYBR Green I Master, and 1 µM of telomere specific 
or 36B4 specific primers reported previously [27]. The 
cycling conditions were as follows: initial denaturation 
at 95 °C 10 min; amplification for 35 cycles consisting of 
95 °C 30 s, 58 °C 10 s, 72 °C 10 s; melting 95 °C 5 s, 70 °C 
1 min, 95 °C continuous; cooling 40 °C 30 s.
The standard curve consisted of twofold dilution series 
from 60 to 0.94 ng, and was done in quintuplicate each 
for the telomere (PCR efficiency 1.91) and 36B4 (PCR 
efficiency 1.98) assays using K562 reference DNA. The 
standard curves were saved externally and imported into 
each PCR run at the time of analysis. The 30  ng point 
in the standard curve was carried in each PCR run and 
marked as the “standard point” to link with the external 
standard curve. The T/S ratio can be calculated using two 
methods: the ΔΔCt method using the Cp (crossing point) 
values or the standard curve nanogram (ng) method. 
T/S ratios calculated by both methods in this study were 
highly concordant based on the strength of linear rela-
tionship  (R2 =  99%). We used the T/S ratios calculated 
by the standard curve (ng) method for the analyses in this 
study [28].
Prior to using the T/S ratio assay with study sam-
ples, we evaluated its reproducibility and validated it in 
comparison to southern blot hybridization-based ter-
minal restriction fragment (TRF) length method using 
TeloTAGGG Telomere Length Assay kit (Roche Life 
Science). For both reproducibility and validation tests, 
PAXgene DNAs from 20 volunteer samples, extracted 
and evaluated similar to study samples were used. T/S 
ratios determined on 2 different days on the same set of 
samples were highly reproducible based on the measure 
of linear relationship  (R2 = 94%) and coefficient of vari-
ation (CV, 3.30%). TRF length expressed in base pairs 
(bp) and T/S ratio showed a strong linear relationship 
 (R2 = 0.78%) slightly higher than that previously reported 
 (R2 = 68%) [26].
Quality control of the assay was done at multiple lev-
els including evaluation of assay reproducibility and vali-
dation. Further, each reaction was run in triplicate, with 
both telomere and 36B4 reactions for each sample run in 
the same 96-well plate to minimize variability. With each 
PCR run, there were 11 study samples along with a repre-
sentative dilution of the standard curve point (30 ng dilu-
tion), 3 volunteer DNA samples to assess plate-to-plate 
variability, and a negative water control. Over the 87 runs 
required to complete the study, the CV for the standard 
curve 30 ng point (reference DNA) and the 3 control vol-
unteer DNA samples ranged from 6.15 to 8.19%. Based 
on this range of CV, we used a cutoff of CV ≤ 10% within 
sample T/S ratio to identify samples for repeat testing. In 
addition, a cutoff CV of ≤  2% was used for the Cp val-
ues within sample triplicates in either the telomere or 
36B4 assays. Sixty-eight samples were repeated in order 
to bring the T/S ratio CV to  ≤  10%. An additional 82 
samples were diluted and repeated in order to fit the Cp 
values within the dynamic range of the standard curve. 
After all quality control measures, the mean CV of all 
tested samples (n = 705) was 0.50 and 0.23% for the Cp 
values of telomere and 36B4 respectively, and 4.39% for 
T/S ratio (median: 4.04%; range: 0.07–9.84%).
Statistical analyses
Data were explored to assess frequency distribution and 
normality. Normality test results and quantile–quan-
tile plots showed that a transformation of T/S ratios did 
not significantly improve normality. As previous stud-
ies have found [29], log-transformation did make T/S 
ratios distribution more normal-like, we compared the 
results using log-transformed and untransformed data 
in preliminary analyses and did not find any significant 
difference. Therefore, the results from the analysis of the 
untransformed T/S ratio are presented. We used gen-
eral linear models to estimate the association of CFS or 
T/S ratio with demographics and clinical measures. We 
adjusted the association of T/S ratio and CFS for covari-
ates that showed significant association with T/S ratio in 
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this study. We summarized associations, unadjusted and 
adjusted for covariates, and considered p-values below 
0.05 to be statistically significant. Age- and sex-stratified 
analyses were also performed to investigate how these 
demographics moderate the association between CFS 
status and T/S ratio. The relationship of T/S ratio to 
mean TRF length (y = 4235x + 5303.8) determined from 
the 20 volunteer subjects was used to convert T/S ratio of 
a sample to mean TRF length in base pairs (bp) where x 
represents the T/S ratio. We estimated years of additional 
aging based on literature value for telomere attrition of 
31–63 bp/year across 20–95 years of adulthood [5].
Results
Table  1 provides demographic and clinical character-
istics of the study sample (n  =  639). The sample was 
mostly female (75%), white (76%), living in a rural area 
(50%), earning an annual income higher than $40,000 
(71%), with mean age of 48 years ±  standard error of 
mean (SEM) of 0.38 and mean BMI of 28  ±  0.21  kg/
m2. The sample was classified into four illness groups: 
CFS-X (12%), CFS (10%), ISF (47%), and NF (31%). 
The groups did not differ in their mean age, residential 
areas, and illness duration but differed significantly for 
measures of abdominal obesity (BMI and WHR), sex, 
race, education, income and PEM.
Table  2 provides estimates for bivariate associa-
tions with illness groups; selected biological measures 
included telomere length, metabolic, and allostatic load 
variables. Overall T/S ratio ranged from 0.269 to 4.138 
(mean: 0.98; median: 0.917). The mean telomere length 
differed significantly by illness group (p = 0.0017); the 
T/S ratio in CFS (0.90 ± 0.03) and ISF-all (0.94 ± 0.02) 
groups were each significantly lower than the NF group 
(1.06 ± 0.04). Triglyceride level, a measure of metabolic 
syndrome, was significantly different among the illness 
groups, but other measures included in both metabolic 
syndrome and allostatic load (HDL, both systolic and 
diastolic blood pressure and fasting glucose levels) did 
not differ significantly. Among the measures specific 
to allostatic load, heart rate, insulin and CRP showed 
Table 1 Participants’ characteristics by illness groups
a Values for age, BMI, WHR and illness duration are mean (SEM). Values for all other characteristics are number of participants with percentages in parenthesis
b Number of subjects with information on illness duration were 86, 47 and 39 corresponding to columns All, CFS-X and CFS
Characteristicsa All
(n = 639)
CFS-X
(n = 77, 12%)
CFS
(n = 64, 10%)
ISF
(n = 302, 47%)
NF
(n = 196, 31%)
p-value
Age, mean (SEM) 48.07 (0.38) 49.99 (1.11) 47.75 (1.21) 48.06 (0.58) 47.44 (0.68) 0.2725
BMI, mean (SEM) 28.13 (0.21) 28.29 (0.56) 28.86 (0.68) 28.82 (0.32) 26.77 (0.36) 0.0003
WHR (SEM) 0.85 (0.00) 0.85 (0.01) 0.85 (0.01) 0.86 (0.004) 0.83 (0.01) 0.0025
Sex 0.0009
 Female 477 (74.64%) 64 (83.12%) 58 (90.63%) 222 (73.51%) 133 (67.87%)
Race 0.0127
 White 488 (76.37%) 60 (77.92%) 51 (79.69%) 219 (72.51%) 158 (80.61%)
 Black 139 (21.75%) 13 (16.88%) 10 (15.63%) 79 (26.16%) 37 (18.88%)
 Other 12 (1.87%) 4 (5.19%) 3 (4.69%) 4 (1.32%) 1 (0.51%)
Residential area 0.1621
 Urban 216 (33.80%) 26 (33.77%) 22 (34.38%) 109 (36.09%) 59 (30.10%)
 Metro 106 (16.58%) 7 (9.09%) 7 (10.94%) 49 (16.23%) 43 (21.94%)
 Rural 317 (49.61%) 44 (57.14%) 35 (54.69%) 144 (47.68%) 94 (47.96%)
Education < 0.0001
 Less than High School 34 (5.33%) 13 (16.88%) 2 (3.13%) 14 (4.65%) 5 (2.56%)
 ≥ HS ≤ 2 year College 349 (54.78%) 51 (66.23%) 40 (62.50%) 177 (58.80%) 81 (41.54%)
 4‑year College 110 (17.27%) 5 (6.49%) 7 (10.94%) 47 (15.61%) 51 (26.15%)
 Graduate 144 (22.60%) 8 (10.39%) 15 (23.44%) 63 (20.93%) 58 (29.74%)
Income < 0.0001
 ≤ $20,000 78 (12.74%) 22 (31.88%) 9 (14.75%) 41 (14.04%) 6 (3.16%)
 $20,001–$40,000 102 (16.67%) 9 (13.04%) 12 (19.67%) 59 (20.21%) 22 (11.58%)
 ≥ $40,001 432 (70.59%) 38 (55.07%) 40 (65.57%) 192 (65.75%) 162 (85.26%)
Illness duration in year, mean (SEM)b 10.99 (0.95) 9.83 (1.10) 12.40 (1.61) Not applicable Not applicable 0.1796
Post‑exertional malaise
 Yes 191 (29.89%) 65 (84.42%) 52 (81.25%) 70 (23.18%) 4 (2.04%) < 0.0001
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Table 2 Association of biological measures with illness groups: selected measures included telomere length, metabolic, 
and allostatic load variables
Values are mean (SEM) unless otherwise indicated
a T/S ratio of a subject is the ratio of telomere PCR signal (T) to the single copy gene PCR signal (S). The T/S ratio is proportional to the average telomere length per cell 
and is expressed relative to the T/S ratio of a reference DNA
b Metabolic syndrome variable
c Allostatic load variable
Variable All
(n = 639)
CFS-X
(n = 77)
CFS
(n = 64)
ISF
(n = 302)
NF
(n = 196)
p-value
T/S ratio telomere  lengtha 0.98 (0.01) 0.97 (0.04) 0.90 (0.03) 0.94 (0.02) 1.06 (0.04) 0.0017
Triglycerides (mg/dL)b 117.13 (3.51) 144.01 (12.15) 143.53 (16.4) 114.25 (4.81) 102.43 (4.62) 0.0003
HDL (mg/dL)b,c 53.86 (0.65) 54.45 (2.29) 52.06 (1.92) 53.31 (0.91) 55.05 (1.16) 0.5278
Heart rate (bpm)c 68.02 (0.35) 69.91 (1.01) 69.05 (1.2) 68.33 (0.5) 66.47 (0.6) 0.0113
Blood pressure: systolic (mmHg)b,c 118.52 (0.61) 120.14 (1.99) 119.34 (1.91) 118.75 (0.92) 117.28 (0.95) 0.4935
Blood pressure: diastolic (mmHg)b,c 74.92 (0.39) 76.29 (1.29) 74.42 (1.32) 74.97 (0.56) 74.48 (0.66) 0.5685
Fasting glucose (mg/dL)b,c 94.35 (0.63) 96.68 (2.02) 93.36 (1.84) 95.5 (1.04) 91.98 (0.8) 0.0501
Insulin (µIU/mL)c 6.29 (0.26) 7.68 (0.92) 6.91 (0.74) 6.64 (0.39) 5.01 (0.39) 0.0062
CRP (mg/dL)c 3.62 (0.2) 5.1 (0.76) 4.71 (0.79) 3.73 (0.28) 2.54 (0.26) 0.0003
Albumin (g/dL)c 4.2 (0.01) 4.23 (0.03) 4.22 (0.03) 4.18 (0.01) 4.22 (0.02) 0.2336
significant differences, with mean CRP level in CFS-X 
and CFS groups being 93% greater than in NF group.
Estimates for bivariate associations of T/S ratio with 
demographic, metabolic and allostatic load variables 
are given in Table  3. We observed a significant inverse 
association of telomere length with age (β: −  0.0051, 
p  =  0.0009.), measures of abdominal obesity [BMI (β: 
− 0.0067, p = 0.0145), WHR (β: − 0.4357, p = 0.0149)] 
and PEM (β: − 0.0521, p = 0.0153). Telomere length was 
also significantly associated with education attainment 
(p  =  0.0288). Telomere length was not statistically sig-
nificantly related to any other demographic or biologi-
cal measurements, although associations with CRP (β: 
− 0.0054, p = 0.0789) and fasting glucose (β: − 0.0017; 
p = 0.0625) were close to statistical significance.
We further adjusted the association of mean telomere 
length with illness groups for previously defined covari-
ates: age, BMI, WHR, PEM and education attainment. 
Sex was also included in the adjustment because of its 
significant association with CFS (Table 1). The mean tel-
omere length differences between all fatigue groups (CFS, 
CFS-X, ISF) and the non-fatigued group remained signif-
icant (p < 0.01) before and after adjustment for covariates 
(Table 4). Based on the adjusted group means, telomere 
length was shorter by 635, 254 and 424 bp in CFS, CFS-X 
and ISF, respectively, compared to NF group. This shorter 
telomere length translates to roughly 10.1–20.5, 4.0–8.2 
and 6.6–13.7 years of additional aging in CFS, CFS-X and 
ISF compared to NF groups, respectively, in the overall 
study sample (Table 4).
The significant negative linear correlation between 
telomere length and age in the overall study sample 
(Table  3) was driven by the statistically significant rela-
tionship among NF participants. For participants in their 
second or third decade, telomere length was longest for 
the NF group (Fig. 1). Age trends for the NF groups indi-
cated a shortening of 42 bp/year (β: − 0.010, p = 0.006) 
whereas the rates for the other groups were not signifi-
cant [CFS (17  bp/year; β: −  0.004, p  =  0.267), CFS-X 
(22 bp/year; β: − 0.005, p = 0.276) and ISF (8.5 bp/year; 
β: − 0.002, p = 0.226)]. As shown in Fig. 1, the significant 
association of telomere length with illness groups was 
restricted to participants  <  45  years old (n  =  216). For 
those < 45 years of age, telomeres were shorter by 932 bp 
in CFS, 767 bp in CFS-X and 966 bp in ISF compared to 
NF participants which translates to roughly 14.8–30.1, 
12.2–24.7 and 15.3–31.8 years of additional aging in the 
CFS, CFS-X and ISF groups, respectively, compared to 
the NF group (Table 5).
While there was no association between telomere 
length and sex in the overall study sample (Table 3), the 
expected male/female difference was seen in the NF 
group; telomeres were 713 bp longer for women (n = 133; 
T/S ratio 1.116) than males (n  =  63; T/S ratio 0.9476) 
(Fig. 2). Analyses stratified on sex (Table 6) showed that 
the significant association of telomere length with ill-
ness groups was restricted to females (n = 477). Within 
female participants, telomeres in the CFS group (n = 58) 
were shorter by 957 bp (β: − 0.226, p < 0.001) compared 
to the NF group (n = 133). Relative to NF, the difference 
was 690 bp in CFS-X (n = 64; β: − 0.163, p = 0.003) and 
711  bp in ISF (n =  222; β: −  0.168, p  <  0.001) groups, 
respectively. In support of this sex-specific effect, tel-
omere length remained without significant difference 
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among male participants in analysis that combined all 
males (n = 99) in the CFS, CFS-X and ISF into one group 
with reference to NF (n = 63).
While the mean telomere length for all illness groups 
was consistently lower than for the NF group in all strati-
fied analyses, the biggest difference was seen in the sub-
set of females < 45 years old (n = 175) (Fig. 3). The extent 
of telomere shortening for females  <  45  years of age in 
each illness group compared to NF was 1130 bp in CFS, 
1007  bp in CFS-X, and 1154  bp in ISF which translates 
to an average 17–35  years of additional aging in CFS, 
CFS-X and ISF. Although sample size becomes limit-
ing with additional nested analyses, within the subset of 
females  <  45  years old, 95% of those with CFS (21/22) 
had telomeres shorter than the mean telomere length 
(T/S ratio = 1.2324) of the NF group (OR = 15.75, 95% 
CI = 1.978–125.412, p = 0.0092) (Additional file 1: Fig-
ure S1).
Discussion
To our knowledge, this is the first study demonstrat-
ing telomere attrition in patients with ME/CFS that 
remained significant before and after adjustment for age, 
sex, obesity (BMI, WHR), PEM and education attain-
ment. Further, stratified analyses based on age and sex 
showed that this association of short telomeres with ME/
CFS is largely moderated by female subjects  <  45  years 
old. In agreement with studies of the general popula-
tion, our study sample showed an inverse association of 
telomere length with age but, interestingly, the associa-
tion was statistically significant only for NF participants. 
The age-related difference in telomere length was more 
pronounced before the 4th decade of life, and stratified 
analysis indicated that the significant association of tel-
omere length with fatigue groups was restricted to par-
ticipants < 45 years old. Similar to findings in this study, 
other researchers have found that premature telomere 
attrition was more significant in patients with lupus ery-
thematosus [30] and rheumatoid arthritis [31] who were 
younger than 40–45 years old.
Overall, and in agreement with studies of the general 
population [32–34], telomeres were significantly longer 
for females compared to males in the NF group. How-
ever, this sex-related difference in telomere length was 
not observed among the fatigue groups (CFS, CFS-X and 
ISF). When the analysis of telomere length by illness clas-
sification was stratified by sex, telomere shortening in 
reference to NF subjects was significant only for females. 
However, telomere length remained without significant 
difference among male participants in analysis that com-
bined all males in the CFS, CFS-X and ISF into one group 
with reference to NF implying that the sex-specific effect 
is unlikely due to difference in sample size. In the gen-
eral population, the ovarian steroid hormone estrogen 
has been proposed to play a role in maintaining long tel-
omeres and increased longevity in females compared to 
males by stimulating telomerase in specific target cells or 
by reducing the burden of oxidative stress due to estro-
gen’s effect on reactive oxygen species (ROS) [35]. Low 
estrogen levels were reported to be associated with short 
telomeres in women [36]. CFS has a higher prevalence in 
females and gynecologic factors such as early menopause 
and hysterectomy have been associated with CFS [20, 37, 
38]. These prior findings along with our observation of 
Table 3 Association of  demographic and  biological 
measures with telomere length
a T/S ratio of a subject is the ratio of telomere PCR signal (T) to the single copy 
gene PCR signal (S). The T/S ratio is proportional to the average telomere length 
per cell and is expressed relative to the T/S ratio of a reference DNA
Variable Telomere length (T/S ratio)a
β (standard error) p-value
Age − 0.0051 (0.0015) 0.0009
BMI − 0.0067 (0.0027) 0.0145
WHR − 0.4357 (0.1784) 0.0149
Sex (female vs. male) 0.0333 (0.0339) 0.3260
Race 0.6062
 White Reference
 Black 0.0326 (0.0358) 0.3633
 Other − 0.0381 (0.1089) 0.7264
Residential area 0.9128
 Urban Reference
 Rural − 0.0016 (0.0329) 0.9607
 Metro 0.0159 (0.0442) 0.7199
Education 0.0288
 Less than High School 0.1176 (0.0707) 0.0970
 ≥ HS ≤ 2 year College 0.1016 (0.0367) 0.0059
 4‑year College 0.0365 (0.0470) 0.4381
 Graduate Reference
Income 0.1298
 ≤ $20,000 − 0.0925 (0.0460) 0.0445
 $20,001–$40,000 − 0.0226 (0.0411) 0.5821
 ≥ $40,001 Reference
Post‑exertional malaise
 Yes vs. no − 0.0521 (0.0321) 0.0153
Triglycerides (mg/dL) − 0.0002 (0.0002) 0.3426
HDL (mg/dL) 0.0004 (0.0009) 0.6233
Heart rate (bpm) − 0.0006 (0.0017) 0.7009
Blood pressure: systolic (mmHg) − 0.0011 (0.0010) 0.2367
Blood pressure: diastolic (mmHg) 0.0005 (0.0015) 0.7211
Fasting glucose (mg/dL) − 0.0017 (0.0009) 0.0625
Insulin (µIU/mL) − 0.0009 (0.0022) 0.6856
CRP (mg/dL) − 0.0054 (0.0030) 0.0789
Albumin (g/dL) 0.0487 (0.0621) 0.4332
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Fig. 1 Profile of mean T/S ratio by illness group and age‑by‑decade in the overall study population (n = 639). Values shown are mean T/S ratio with 
SEM
short telomeres in female participants < 45 years old with 
CFS, CFS-X and ISF suggest the need for further studies 
on the dynamics of telomere length in relation to age, sex 
hormones, gynecological history and the onset of CFS.
For a wide variety of chronic diseases, elevated levels 
of inflammatory markers like CRP and cytokines such 
as interferon-γ (IFN-γ), tumor necrosis factor a (TNF-
a), interleukin 1 and 6 (IL-1, IL-6), have been reported 
to be associated with disease progression, poor quality 
of life and poor therapeutic outcomes [39–45]. These 
reports include diabetes, chronic obstructive pulmonary 
disease, renal failure, psychiatric/neurological disorders, 
cardiovascular disease and other chronic/autoimmune/
infectious diseases, including ME/CFS. Accelerated 
shortening of telomeres was also reported in many of 
these same chronic/autoimmune diseases. In most cases 
Table 4 Adjusted T/S ratio means, calculated TRF length difference and accelerated aging in fatigued groups with respect 
to NF in the study sample (n = 639)
** p < 0.01
a Adjusted for sample characteristics including age, sex, education, BMI, WHR and PEM
b TRF length (bp) refers to terminal restriction fragment length in base pairs
c Values outside and inside the parenthesis represent those based on unadjusted and adjusted mean T/S ratios, respectively
CFS status Unadjusted
T/S ratio means (SEM)
F = 5.13**
Adjusted
T/S ratio means (SEM)a
F = 2.61**
Mean TRF length (bp) difference 
with respect to  NFb,c
Equivalent additional years 
in aging with respect to  NFc
CFS 0.90 (0.03) 0.90 (0.05) 673 (635) 10.7–21.7 (10.1–20.5)
CFS‑X 0.97 (0.04) 0.99 (0.05) 360 (254) 5.7–11.6 (4.0–8.2)
ISF 0.94 (0.02) 0.95 (0.03) 500 (424) 7.9–16.1 (6.6–13.7)
NF 1.06 (0.04) 1.05 (0.04) Reference Reference
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inflammation and telomere shortening were studied sep-
arately and a cause-effect relationship between these two 
processes occurring in the same cells remains to be elu-
cidated [40, 46, 47], although it is proposed that both tel-
omere shortening and inflammation may be involved in 
a bidirectional cause-effect relationship. Telomere attri-
tion may directly act as a strong inducer of pro-inflam-
matory cytokines in different cell types during aging (a 
phenomenon called senescence associated secretory phe-
notypes, SASP), or that chronic inflammation may cause 
telomere/telomerase dysfunction directly through pro-
duction of ROS resulting in telomeric DNA damage [40, 
48]. Both possibilities may explain the recently reported 
inverse relationship of telomere length with oxidative 
stress and levels of IL-6 (a component of SASP) in sub-
jects with depression [46]. It is interesting to note that 
Table 5 Significant telomere attrition in  CFS and  ISF in  comparison to  NF in  analysis restricted to  participants 
under 45 years old
Data not shown for participants ≥ 45 years old (n = 423) since there was no significant difference in telomere length between illness groups
a TRF length (bp) refers to terminal restriction fragment length in base pairs
CFS-status 
(participants < 45 years old, 
n = 216)
T/S ratio Mean TRF length (bp) difference 
with respect to  NFa
Equivalent additional years 
in aging with respect to NF
β SE p-value
CFS (n = 24) vs. NF (71) − 0.220 0.0927 0.018 932 14.8–30.1
CFS‑X (n = 19) vs. NF − 0.175 0.1014 0.085 767 12.2–24.7
ISF (n = 102) vs. NF − 0.227 0.0607 < 0.0001 966 15.3–31.2
Table 6 Significant telomere attrition in  CFS, CFS-X and  ISF in  comparison to  NF in  analysis restricted to  female 
participants only
Data not shown for male participants since there was no significant difference in telomere length between illness groups in male participants (n = 162)
a TRF length (bp) refers to terminal restriction fragment length in base pairs
CFS-status (all female, n = 477) T/S ratio Mean TRF length (bp) 
difference with respect to  NFa
Equivalent additional years 
in aging with respect to NF
β SE p-value
CFS (n = 58) vs. NF (n = 133) − 0.226 0.0566 < 0.0001 957 15.2–30.9
CFS‑X (n = 64) vs. NF − 0.163 0.0548 0.003 690 11.0–22.3
ISF (n = 222) vs. NF − 0.168 0.0395 < 0.0001 711 11.3–23.0
Fig. 2 Profile of mean T/S ratio stratified by sex and by illness group in the overall study population (n = 639). Values shown are mean T/S ratio with 
SEM
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senescence markers like IL-6 and  p16INK4a were associ-
ated with increased risk of developing cancer fatigue 
syndrome from cytotoxic chemotherapy [48, 49]. Elimi-
nation of senescent cells in an animal model of chemo-
therapy-induced fatigue almost entirely rescued normal 
physical activity [48, 49]. The incidence of severe fatigue 
in breast cancer patients correlated with the highest lev-
els of  p16INK4a suggests that an increased total burden 
of senescent cells may cause fatigue [48, 49]. We found 
significant association of ME/CFS with higher levels of 
CRP, and marginal association of higher levels of CRP 
with shorter telomeres in this study. A similar inverse 
but stronger association of CRP and telomere length was 
reported recently in relation to cardiovascular disease 
risk [50] and obesity [51]. It is likely that pro-inflamma-
tory cytokines may stimulate production of CRP [51, 
52] that may in turn contribute to telomere shortening 
through oxidative stress [51, 53]. In combination with 
these prior studies, our observations suggest chronic 
inflammation and/or oxidative stress may contribute to 
accelerated telomere shortening or vice versa in at least 
a subset of subjects with ME/CFS. Further, aging-related 
fundamental and translational studies may provide prom-
ising avenues to assess the risk and therapeutic approach 
using the new class of senolytic drugs that target senes-
cent cells to alleviate symptoms of ME/CFS [49, 54].
Mitochondrial function also declines with age, primar-
ily in the form of impaired ATP production and increased 
production of ROS, both of which are associated with 
chronic diseases. While details of the potential inter-play 
between telomere shortening and mitochondrial dysfunc-
tion are unknown, many chronic diseases like metabolic, 
cardiovascular and neurodegenerative diseases, diabetes, 
mood and other psychological disorders with demon-
strated telomere shortening are also associated with mito-
chondrial dysfunction and oxidative stress that may cause 
DNA damage [55]. Recent metabolomic findings [56–58] 
suggest ME/CFS is a hypometabolic syndrome that may 
relate to mitochondrial dysfunction. These studies also 
found the metabolomics of ME/CFS to be sex-specific 
[56]. Additional studies exploring the relationship between 
sex-specific hypometabolic state and telomere attrition 
could help understand the pathophysiology of ME/CFS.
There are several strengths to this explorative study on 
the association of telomere length with CFS. These include 
a relatively large overall study sample (n = 639) consisting 
of participants grouped into four illness status (CFS, CFS-
X, ISF and NF), adjustment of illness status and telomere 
length with a number of demographic and biological 
measures, and validation of the qPCR method for repro-
ducibility and agreement with southern blot hybridization-
based TRF length method. The study also has weaknesses, 
including the cross-sectional design and inability to evalu-
ate or control for duration of illness and medication used. 
The qPCR method provides only global mean length of 
telomeres and does not recognize individual short telom-
eres or provide information of the extend of pathologically 
critical short telomeres [59]. In this sense, diagnostic util-
ity of telomere length determination by qPCR is limited 
but it is comparable with other methods in terms of its 
Fig. 3 Distribution of mean T/S ratio stratified by age and sex among illness groups. Values shown are mean T/S ratio with SEM
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accuracy for association studies of telomere length with 
diseases [60]. A further limitation of our assay is that we 
used DNA extracted from whole blood consisting of lym-
phocytes, monocytes and granulocytes. Thus the telomere 
length determined in this study represents only the mean 
telomere length of different blood cell types instead of 
blood cell type-specific or telomere length distribution of 
different chromosomes in a given cell type.
Conclusion
This study demonstrates a significant association of ME/
CFS with premature telomere attrition, largely moder-
ated by female subjects < 45 years old. Our results need 
to be replicated independently using a large sample size 
and with methods that can add improved diagnostic 
value to telomere length measurement. This observa-
tion of shorter telomeres along with reports of low- or 
high-grade inflammation mediated by pro-inflammatory 
cytokines and metabolic decline/mitochondrial dysfunc-
tion provide multiple levels of support to include ME/
CFS to the list of conditions associated with acceler-
ated aging that could be triggered by genetic, epigenetic, 
infection, stress or other environmental factors. Further 
work is needed to evaluate the functional significance, 
and the specific contribution of genetic, epigenetic and 
environmental factors to accelerated aging in ME/CFS.
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